COVID-19 therapeutics tracker

TrackersTrackers
| 01 July 2022 | By Jeff Craven 

A handful of therapeutics have been approved specifically to treat COVID-19, reduce its severity, or prevent it entirely.
 
As of July 2022, those treatments include dexamethasone, Avigan (favilavir), Veklury (remdesivir) alone and in combination with Olumiant (baricitinib), Lagevrio (molnupiravir), Xevudy (sotrovimab), Regkirona (regdanvimab), Ronapreve (casirivimab and imdevimab), amubarvimab and romlusevimab (formerly BRII-196 and BRII-198), Actemra/RoActemra (tocilizumab), Paxlovid (nirmatrelvir + ritonavir), and Kineret (anakinra). Evusheld (tixagevimab and cilgavimab; AZD7442) has been authorized in several countries for use as pre-exposure prophylaxis. Regulators around the world have allowed many other additional treatments to be used on an emergency-use basis.
 
A key ongoing focus in developing COVID-19 treatments will be the efficacy of therapeutics against current and emergent SARS-CoV-2 variants. Therapeutics that are effective against one version of the virus, for example, may be significantly less effective or even ineffective against a new variant. Whenever possible, we will describe how these therapeutics work against the dominant variants circulating throughout the world.
 
Updated 01 July with new information on Paxlovid, Evusheld, molnupiravir, Regkirona and ivermectin.

This tracker is no longer being regularly updated. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at news@raps.org.



 

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

5;16;25;